Summary of Conference Call for Bailong Chuangyuan Company Overview - **Company**: Bailong Chuangyuan - **Industry**: Dietary Fiber and Functional Sugar Key Points Sales and Production - In 2025, total dietary fiber sales exceeded 48,000 tons, with polydextrose at approximately 21,000 tons and resistant dextrin at about 27,000 tons. Resistant dextrin sales grew nearly 50% year-on-year, while polydextrose saw a decline of about 20% due to capacity constraints, not weak demand [2][7] - The sales volume of allulose in 2025 was slightly over 10,000 tons, with a year-on-year growth of less than 30%. Prices decreased by 10%-20% due to upstream raw material price influences [2][8] - A new capacity project for 20,000-30,000 tons of dietary fiber is in the commissioning phase, expected to contribute to revenue and profit starting in Q2 2026 [2][12] Profit Margins - The company expects overall gross margins in 2026 to remain stable compared to 2025. Polydextrose gross margin is around 20%, resistant dextrin is approximately 50%-60%, and other prebiotic products are about 30% [4][13] - Allulose gross margin improved by less than 10 percentage points in 2025, attributed to new production lines and upstream raw material cost reductions [9][15] Market Trends and Product Development - The introduction of prebiotic beverages by major overseas brands reflects ongoing trends in health and nutrition. Domestic manufacturers are expected to launch similar products in 2026 [5][6] - The potential impact of a "sugar tax" policy in China is uncertain, but it could stimulate the alternative sugar market significantly if implemented [3] Capacity and Production Strategy - The company prioritizes high-value-added products in its capacity arrangements without setting rigid production ratios or gross margin targets [4][14] - The Thai factory is expected to commence production in 2027, with raw material sourcing differing from domestic operations [17][18] Market Position and Growth Potential - The company holds a market share of approximately 20%-30% in resistant dextrin globally and 30%-40% in allulose, making it the largest supplier [20] - The growth of the dietary fiber market is driven by increasing health awareness and innovation in end products, with a projected mid-term growth rate for allulose sales of 20%-30% or higher [10][21] Financial Guidance - The company targets a revenue and profit growth of no less than 25%-30% in 2026, driven by new capacity and domestic market product launches [24][25] Challenges and Considerations - Price remains a key constraint for allulose, which currently has the highest production cost among alternative sugars. Increased health awareness and consumer education are necessary for market expansion [11] - The company is cautious about predicting industry demand and growth due to limited public data and uncertainties in overseas expansion [22][23] Additional Insights - The company is actively involved in R&D and technical reserves for allulose, with several manufacturers already preparing for market entry [9][10] - The domestic beverage market is likely to adopt allulose more readily due to its larger size and the feasibility of producing sugar-free products [10]

Core Viewpoint - Excessive sugar intake poses significant health risks, including obesity, diabetes, cardiovascular diseases, and dental issues, as highlighted by the World Health Organization (WHO) guidelines [1][2][3][4][5]. Group 1: Health Risks of Excess Sugar Consumption - High sugar diets are linked to increased all-cause mortality and reduced healthy lifespan [2][24]. - Excessive sugar can lead to obesity, which is a risk factor for various cancers [2]. - Long-term high sugar intake can result in cardiovascular diseases due to fat accumulation [3]. - Overconsumption of sugar can decrease insulin sensitivity, raising the risk of type 2 diabetes, with over 60% of type 2 diabetes patients being overweight or obese [4]. - Frequent sugar consumption creates a favorable environment for bacteria in the mouth, leading to dental caries and other oral diseases [5]. - Sugar can convert to fat, contributing to fatty liver disease and other organ-related fat accumulation [6]. - High sugar intake accelerates skin aging through chronic inflammation and oxidative stress [7]. Group 2: Healthier Sugar Alternatives - Black sugar is recommended for its health benefits, including warming properties and blood nourishment, but should be consumed in moderation (maximum 50 grams daily, ideally 25 grams) [8][11][17]. - Beta-glucan, a natural polysaccharide, helps regulate blood sugar and lower cholesterol [13]. - Oligofructose, a soluble dietary fiber, aids in preventing constipation and stabilizing blood sugar levels [14][15]. Group 3: Guidelines for Healthy Sugar Consumption - Control total sugar intake, adhering to the guideline of no more than 50 grams per day, ideally limiting to 25 grams [17][26]. - Be cautious of hidden sugars in food products, checking labels for various types of sugars [19]. - Limit the use of high-sugar cooking methods and sauces, as they can significantly increase sugar intake [20]. - Be aware of artificial sweeteners in "low sugar" or "sugar-free" products, which may still pose health risks if consumed excessively [21][22]. - Increase physical activity to offset excess sugar intake [23][26].

Core Viewpoint - Excessive sugar intake poses significant health risks, including obesity, diabetes, cardiovascular diseases, and dental issues, as highlighted by the World Health Organization (WHO) [1][2] Group 1: Health Risks of Excessive Sugar Intake - High sugar consumption is linked to an increased risk of various chronic diseases, including obesity, type 2 diabetes, cardiovascular diseases, and dental cavities [1][4][6] - Epidemiological studies indicate that individuals with high sugar diets have a higher all-cause mortality risk and a noticeable impact on healthy lifespan [2] - Overconsumption of sugar can lead to obesity, which is a known risk factor for several types of cancer [3] - Long-term high sugar intake can result in fat accumulation, increasing the risk of cardiovascular diseases [4] - Excessive sugar can decrease insulin sensitivity, raising the risk of diabetes, with over 60% of type 2 diabetes patients being overweight or obese [5] - Frequent sugar consumption creates a favorable environment for bacteria in the mouth, leading to dental issues [6] - High sugar intake can contribute to fatty liver disease and other organ-related fat accumulation [7][8] - Increased sugar consumption can accelerate skin aging due to chronic inflammation and oxidative stress [9] Group 2: Healthier Sugar Alternatives - Black sugar is recommended in moderation for its health benefits, such as aiding in blood nourishment and alleviating certain health conditions [10][13] - β-glucan, a natural polysaccharide, helps regulate blood sugar and improve cholesterol levels [15][16] - Oligofructose, a soluble dietary fiber, can aid in preventing constipation and improving nutrient absorption [18][19] Group 3: Guidelines for Healthy Sugar Consumption - The recommended daily intake of added sugars should not exceed 50 grams, ideally limited to 25 grams [20] - It is important to be aware of hidden sugars in food products by checking labels, as many items contain significant amounts of added sugars [22] - Cooking methods that involve high sugar content, such as sweet and sour dishes, should be minimized [23] - Increasing physical activity can help offset the caloric intake from sugar [25] - Awareness of low-sugar food standards is essential to ensure health benefits [24]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 28.00 [1]. Core Insights - The company is expected to see a significant acceleration in performance in Q4, driven by high demand and improved capacity utilization. The projected revenue for 2025 is RMB 1.38 billion, representing a year-on-year increase of 19.75%, with net profit expected to reach RMB 370 million, up 48.9% [5][6]. - The company is well-positioned to benefit from the growing demand for functional sugars, with new production capacity expected to come online in 2026, further enhancing revenue growth [7][8]. Financial Projections - Revenue projections for the upcoming years are as follows: - 2024: RMB 1.15 billion (+32.64%) - 2025: RMB 1.38 billion (+19.74%) - 2026: RMB 1.74 billion (+25.99%) - 2027: RMB 2.23 billion (+28.52%) [4]. - Net profit forecasts are: - 2024: RMB 246 million (+27.26%) - 2025: RMB 367 million (+49.45%) - 2026: RMB 471 million (+28.27%) - 2027: RMB 620 million (+31.70%) [4]. - The company’s EPS is projected to increase from RMB 0.58 in 2024 to RMB 1.48 in 2027 [4]. Valuation Metrics - The company’s PE ratio is expected to decrease from 38.44 in 2024 to 15.23 in 2027, indicating improving valuation as earnings grow [4]. - The PB ratio is projected to decline from 5.62 in 2024 to 3.37 in 2027, reflecting a more attractive valuation over time [4]. - The EV/EBITDA ratio is expected to fall from 24.75 in 2024 to 9.79 in 2027, suggesting enhanced operational efficiency and profitability [4].

Core Insights - The company reported a strong performance in the first half of 2025, with revenue of 649 million yuan, a year-on-year increase of 22.18%, and a net profit attributable to shareholders of 170 million yuan, up 42.00% year-on-year [1] - The core products continue to grow rapidly, with overseas demand remaining strong, particularly in the prebiotic series, dietary fiber series, and health sweeteners [1][3] Financial Performance - In Q2 2025, the company achieved revenue of 336 million yuan, a year-on-year increase of 20.29%, and a net profit of 88 million yuan, up 33.84% year-on-year [1] - The gross profit margin for H1 2025 was 40.54%, an increase of 7.07 percentage points year-on-year, while the net profit margin was 26.15%, up 3.65 percentage points year-on-year [2] - The company’s operating expenses slightly increased, with sales, management, finance, and R&D expense ratios at 3.15%, 2.43%, 0.01%, and 3.56%, respectively [2] Product and Capacity Expansion - The approval of D-allohexose as a new food ingredient in July 2025 marks a new phase for the company in the domestic market, with expected growth from previously developed products [3] - The company has two projects under construction aimed at expanding production capacity, including a smart production facility for functional sugars and a health food raw material factory in Thailand [3] - Upon completion, these projects will significantly increase production capacity, particularly for overseas clients, with expected annual outputs of 11,000 tons of isomaltulose, 12,000 tons of crystalline allohexose, and more [3] Profit Forecast - The company is projected to achieve net profits attributable to shareholders of 366 million yuan, 489 million yuan, and 657 million yuan for the years 2025 to 2027, representing year-on-year growth rates of 49%, 33%, and 34%, respectively [3] - The current stock price corresponds to price-to-earnings ratios of 24X, 18X, and 14X for the years 2025 to 2027, maintaining a "strong buy" rating [3]

Core Viewpoint - The company is experiencing significant growth in revenue and profit due to the increasing demand for dietary fiber and allulose sugar, with new production capacities contributing to this trend [1][3]. Financial Performance - For the first half of 2025, the company expects total revenue of 650 million yuan, a year-on-year increase of 22.29%, and a net profit attributable to shareholders of 171 million yuan, up 42.68% [1]. - In Q2 2025, the company anticipates total revenue of 336 million yuan, reflecting a 20.49% year-on-year growth, and a net profit of 89 million yuan, which is a 35.06% increase [1]. Product Demand and Market Trends - The approval of D-allulose as a new food ingredient in China is expected to drive rapid growth in domestic demand, particularly in the baking sector [2]. - D-allulose has a sweetness level of 70% compared to sucrose and can be used in various food products, enhancing flavor and color through the Maillard reaction [2]. Production Capacity and Expansion - The company has established itself as a leader in the allulose market, having developed and industrialized various forms of allulose since 2014 [3]. - The construction of a new factory in Thailand is underway, which will produce 12,000 tons of crystalline allulose and expand the company's international market presence [3]. Profit Forecast - The company is projected to achieve net profits of 361 million yuan, 474 million yuan, and 647 million yuan for the years 2025, 2026, and 2027, representing year-on-year growth rates of 47%, 31%, and 37% respectively [3].

Core Viewpoint - The company is focusing on high-value core products such as prebiotics, dietary fibers, and sugar-reducing sweeteners, which are expected to drive future growth and profitability [2][3][4]. Product Focus - The company's core products include prebiotics (oligomaltose, fructooligosaccharides, galactooligosaccharides), dietary fibers (polydextrose, resistant dextrin), and sugar-reducing sweeteners (erythritol, crystalline fructose, allulose) [2]. Gross Margin Improvement - The gross margin for the company's core products increased from 9.74% in 2023 to 15.84% in 2024, driven by optimized product structure, reduced consumption, and lower procurement costs [3][4]. - The gross margins for individual core products are as follows: prebiotics increased from 19.34% to 24.60%, dietary fibers from 12.64% to 18.12%, and sugar-reducing sweeteners from 1.26% to 9.09% [4]. Production Strategy - The company is implementing a "small, refined, and flexible" production model to cater to differentiated market demands, focusing on high-value, small-batch orders [6]. - The flexible production plan aims to enhance responsiveness to market needs and build competitive advantages through customized products [6]. New Product Development - The company is expanding its product line with high-value products such as DHA algae oil, lactulose, and HMOs, with production capacity already established for these new products [8]. - Strategic partnerships have been formed to ensure sales of new products, with ongoing projects in trial production stages [8]. Market Impact of Tariffs - Following the EU's imposition of anti-dumping duties on erythritol, the company has capitalized on being the lowest taxed entity, resulting in a 123% year-on-year increase in erythritol sales revenue in Q1 2025 [8]. Capacity Expansion - The company has been a pioneer in the domestic allulose market, with a production capacity exceeding 5,000 tons set to be expanded to 20,000 tons in the future [9]. Financial Performance - In Q1 2025, the company reported a revenue of 685 million yuan, a 24.23% increase year-on-year, and a net profit of 50.36 million yuan, up 117.35% year-on-year [10].

Group 1 - The core business of the company is to provide drug discovery, development, and production services for global pharmaceutical companies, biotechnology firms, and research institutions [1] - The CRO/CDMO segment is the company's core business, consisting of four service modules: chemical CRO, biological CRO, small molecule CDMO, and large molecule CDMO [1] - The company is one of the few domestic leaders with full-process service capabilities in preclinical CRO and CMO, ranking among the top three in the preclinical CRO market in China [1] Group 2 - As of the latest quarterly report for Q3 2024, the company achieved a revenue of 719 million yuan, a year-on-year decrease of 15.09% [1] - The net profit for the same period was -61.67 million yuan, reflecting a year-on-year decline of 96.88% [1] - The company's gross profit margin stands at 19.22% [1] Group 3 - The company's latest market performance shows a closing price of 5.88 yuan, an increase of 1.91%, with a current price-to-book ratio of 2.14 and a total market capitalization of 2.928 billion yuan [1] - A total of 31 institutions hold shares in the company, with a combined holding of 2.0099 million shares valued at 13 million yuan [1]

Group 1: Company Development - The company aims to consolidate and expand its leading position in the functional ingredients industry while venturing into end-consumer products and animal nutrition sectors [1] - The national push for the health industry, with prebiotics as a key component, presents broader development prospects influenced by market demand and corporate capabilities [2] Group 2: Product Overview - The company introduced its existing products, including oligomaltose, fructooligosaccharides, erythritol, glucose syrup, and dietary fibers, highlighting their functional characteristics and market applications [2] Group 3: Market Development - The company focuses on market demand and customer value, intensifying efforts in market expansion and application solutions, particularly in the functional food market [2] - Initiatives such as the salt and sugar reduction plans have been implemented this year, alongside the exploration of new fields and products [2]